Daily Ards Research Analysis
Three studies advance care across the ARDS continuum: a randomized trial shows therapeutic plasma exchange accelerates immune recovery in severe COVID-19 despite no effect on ARDS parameters; a neonatal cohort links lung ultrasound patterns and comorbidities (including ARDS and PPHN) to recovery in TTN; and a prospective ARDS study underscores the prognostic value of RV dysfunction quantified by TAPSE.
Summary
Three studies advance care across the ARDS continuum: a randomized trial shows therapeutic plasma exchange accelerates immune recovery in severe COVID-19 despite no effect on ARDS parameters; a neonatal cohort links lung ultrasound patterns and comorbidities (including ARDS and PPHN) to recovery in TTN; and a prospective ARDS study underscores the prognostic value of RV dysfunction quantified by TAPSE.
Research Themes
- Immunomodulatory strategies in severe viral respiratory failure
- Bedside cardiopulmonary monitoring and echocardiography in ARDS
- Neonatal lung ultrasound for outcome prediction
Selected Articles
1. Therapeutic plasma exchange accelerates immune cell recovery in severe COVID-19.
In a registered randomized clinical trial, adding therapeutic plasma exchange to standard care in severe COVID-19 reduced anti-type I IFN autoantibodies and inflammatory mediators and improved lymphopenia and T-cell dysfunction. While ARDS parameters did not improve overall, a subset of patients with early favorable respiratory outcomes showed enhanced virus-specific T-cell responses.
Impact: This is a randomized clinical trial linking a mechanistic intervention (TPE) to comprehensive immune readouts in severe viral respiratory failure. It clarifies that immune recalibration can occur without immediate ARDS parameter change, guiding biomarker-driven strategies.
Clinical Implications: TPE should not be expected to improve ARDS metrics acutely but may be considered in biomarker-selected severe COVID-19 to reverse lymphopenia and T-cell exhaustion, particularly in patients with anti-type I IFN autoantibodies.
Key Findings
- TPE reduced anti-type I IFN autoantibodies and circulating inflammatory mediators (e.g., IL-18, IL-7, CCL2, CCL3).
- TPE did not change ARDS parameters across the protocol compared with standard treatment.
- TPE reversed lymphopenia, prevented T-cell hyperactivation, reduced T-cell exhaustion, and increased memory and virus-specific T cells in patients with early favorable respiratory outcomes.
Methodological Strengths
- Prospective randomized design with trial registration (NCT04751643).
- Deep immunophenotyping including autoantibodies, cytokines, and T-cell functional states.
Limitations
- Sample size and blinding details are not provided in the abstract; likely underpowered for clinical outcomes.
- Lack of improvement in ARDS physiological parameters limits immediate clinical adoption.
Future Directions: Conduct larger, blinded RCTs stratified by anti-IFN autoantibody status to test whether immune recovery translates into improved clinical outcomes and to define optimal timing and dosing of TPE.
BACKGROUND: Immunological disturbances (anti-type I IFN auto-antibody production, cytokine storm, lymphopenia, T-cell hyperactivation and exhaustion) are responsible for disease exacerbation during severe COVID-19 infections. METHODS: In this study, we set up a prospective, randomised clinical trial (ClinicalTrials.gov ID: NCT04751643) and performed therapeutic plasma exchange (TPE) in severe COVID-19 patients in order to decrease excess cytokines and auto-antibodies and to assess whether adding TPE to the standard tr
2. Lung ultrasound to evaluate the outcome and prognosis of transient tachypnea of the newborn.
Among 200 TTN neonates and 200 controls, lung ultrasound patterns varied with disease severity, and recovery averaged 2.3 days but was prolonged with mechanical ventilation needs. Type II respiratory failure, ARDS, PPHN, and heart failure independently prolonged TTN course.
Impact: This study operationalizes lung ultrasound for prognostication in TTN and quantifies clinical factors—including ARDS and PPHN—that prolong recovery, informing neonatal respiratory care pathways.
Clinical Implications: Bedside lung ultrasound can stratify TTN severity and expected recovery time. Coexisting ARDS, PPHN, heart failure, and type II respiratory failure should prompt closer monitoring and respiratory support planning.
Key Findings
- Mean time to full symptom recovery in TTN was 2.3 ± 1.33 days.
- Recovery duration increased with respiratory support level: mild illness 1.42 days, non-invasive ventilation 3.36 days, invasive ventilation 6.00 days.
- Type II respiratory failure, ARDS, PPHN, and heart failure were independent predictors of prolonged TTN course.
Methodological Strengths
- Relatively large sample with contemporaneous controls (200 TTN vs 200 controls).
- Use of multivariate logistic regression to identify independent predictors.
Limitations
- Single-center design with potential selection bias.
- Lung ultrasound protocols and operator dependency may limit generalizability.
Future Directions: Standardize lung ultrasound scoring for TTN across centers and test predictive models incorporating comorbidities (e.g., ARDS, PPHN) in multicenter prospective cohorts.
BACKGROUND/OBJECTIVES: Transient tachypnea of the newborn (TTN) is generally self-limiting. The increasing incidence of severe cases and lack of comprehensive studies on its clinical outcomes and influencing factors highlight the need for improved diagnostic and monitoring tools. This study aimed to assess the lung ultrasonographic features, recovery durations, and factors influencing TTN. METHODS: Two hundred neonates with wet lungs were selected as the TTN group and divided into mild (132/200)
3. Right Ventricular Dysfunction in Acute Respiratory Distress Syndrome and Its Quantification by Tricuspid Annular Plane Systolic Excursion on Transthoracic Echocardiography.
In 40 mechanically ventilated ARDS patients, serial TAPSE measurement via transthoracic echocardiography was used to quantify RV dysfunction, a known predictor of poor outcomes. The study highlights feasibility and potential prognostic value of bedside TAPSE monitoring in the ICU.
Impact: It reinforces a practical, reproducible echocardiographic metric (TAPSE) for RV assessment in ARDS, supporting incorporation into routine ICU monitoring.
Clinical Implications: Routine TAPSE assessment may help identify ARDS patients at risk of RV dysfunction and guide ventilator settings and fluid/vasopressor strategies.
Key Findings
- Prospective ICU study in 40 ventilated ARDS patients quantified RV function with serial TAPSE.
- Findings support TAPSE as a feasible bedside metric to track RV dysfunction in ARDS management.
- Study underscores the prognostic relevance of RV dysfunction in ARDS.
Methodological Strengths
- Prospective design with serial echocardiographic assessments.
- Focus on a standardized, easily obtainable bedside metric (TAPSE).
Limitations
- Small single-center sample limits generalizability and statistical power.
- Lack of detailed outcomes and multivariable adjustment in the abstract.
Future Directions: Validate TAPSE thresholds for risk stratification and integrate RV-focused monitoring into ventilator and hemodynamic protocols in multicenter studies.
Background Right ventricular (RV) dysfunction is a typical complication of acute respiratory distress syndrome (ARDS), which is an independent predictor of poor prognosis in ARDS. Thus, evaluation of RV function is a crucial component of ARDS patient management. The present study aimed to determine the incidence of RV dysfunction by 2D echocardiography in mechanically ventilated ARDS patients in the ICU and assess the serial changes in tricuspid annular plane systolic excursion (TAPSE) among the